Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital
Bibliographic Data
| ID | 16780500 |
|---|---|
| Authors | Maurílio De Souza Cazarim (0000-0002-2826-5903, Universidade de Ribeirão Preto), João Paulo Vilela Rodrigues (0000-0002-5785-1418, Universidade de Ribeirão Preto), Priscila Santos Calcini (0000-0002-5910-3974, Universidade de Ribeirão Preto), Thomas R Einarson (0000-0003-3865-2533, University of Toronto), Leonardo Régis Leira Pereira (0000-0002-8609-1390, Universidade de Ribeirão Preto) |
| Year | 2020 |
| Volume | 54 |
| Pages | 94 |
| Publication date | 2020-11-18 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Revista de Saúde Pública (JOURNAL) |
| Journal identifiers | ISSN: 0034-8910 • E-ISSN: 0034-8910 |
| Publisher | Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais (PUBLISHER) |
| DOI | 10.11606/s1518-8787.2020054001895 |
| PMID | 33027344 |
| OpenAlex | W3091147512 |
| Language | EN |
| Citations received | 1 |
| References cited | 1 |
OBJECTIVE: To perform a cost-benefits analysis of a clinical pharmacy (CP) service implemented in a Neurology ward of a tertiary teaching hospital. METHODS: This is a cost-benefit analysis of a single arm, prospective cohort study performed at the adult Neurology Unit over 36 months, which has evaluated the results of a CP service from a hospital and Public Health System (PHS) perspective. The interventions were classified into 14 categories and the costs identified as direct medical costs. The results were analyzed by the total and marginal cost, the benefit-cost ratio (BCR) and the net benefit (NB). RESULTS: The total 334 patients were followed-up and the highest occurrence in 506 interventions was drug introduction (29.0%). The marginal cost for the hospital and avoided cost for PHS was US$182±32 and US$25,536±4,923 per year; and US$0.55 and US$76.4 per patient/year. The BCR and NB were 0.0, -US$26,105 (95%CI -31,850 – -10,610), -US$27,112 (95%CI -33,160–11,720) for the hospital and; 3.0 (95%CI 1.97–4.94), US$51,048 (95%CI 27,645–75,716) and, 4.6 (95%CI 2.24–10.05), US$91,496 (95%CI 34,700–168,050; p
Average cost · Clinical pharmacy · Cost analysis · Family medicine · Marginal cost · Pharmacist · Prospective cohort study · Psychological intervention · Public health · Total cost · Emergency Medicine · Health Systems, Economic Evaluations, Quality of Life · Internal Medicine · Medicine · Nursing · Pharmaceutical Practices and Patient Outcomes · Pharmacy · Public Health in Brazil · Pediatrics
| Citations per year | 0.17 |
|---|---|
| Citation span | 2020 - 2020 (1) |
| Highly cited | No |